EGFR and non-small cell lung carcinoma: Silencing ofEGFR significantly sensitizes NSCLC cells to erlotinib, suggesting that increased EGFR expression also contributes to NSCLC cell TKI resistance in addition to acquired EGFR resistance mutations.